Tofacitinib and other kinase inhibitors in the treatment of psoriasis;Tofacitinib y otros inhibidores de las cinasas en el tratamiento de la psoriasis

Actas Dermo-Sifiliograficas

Volumn 104, Issue 4, 2013, Pages 304-310

  Ortiz Ibanez K ^a   Alsina, M M ^a   Munoz Santos C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Janus kinase; Kinases; Psoriasis; Ruxolitinib; Small molecules; Tofacitinib; Tyrosine kinase

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; TOFACITINIB;

ARTICLE; BIOLOGICAL THERAPY; PSORIASIS; TOPICAL TREATMENT;

EID: 84876367210     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.ad.2012.10.018     Document Type: Short Survey

References (27)

1. R.B. Warren, and C.E.M. Griffiths The future of biological therapies Semin Cutan Med Surg 29 2010 63 66
2. H. Ben-Bassat, and A. Levitzki Inhibitors of tyrosine kinases in the treatment of psoriasis IMAJ 2 Suppl 2000 69 73
3. T. Pawson Protein modules and signalling networks Nature 16 1995 573 580
4. K. Ghoreschi, A. Laurence, and J.J. O'Shea Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 10 2009 356 360
5. H. Ben Bassat, and B.Y. Klein Inhibitors of tyrosine kinases in the treatment of psoriasis Curr Pharm Des 6 2000 933 942
6. J.M. Kyriakis, and J. Avruch Protein kinase cascades activated by stress and inflammatory cytokines Bioassays 18 1996 567 577
7. S.S. Bhagwat Kinase inhibitors for the treatment of inflammatory and autoimmune disorders Purinergic Signal 5 2009 107 115
8. P.J. Murray The JAK-STAT signaling pathway: input and output integration J Immunol 178 2007 2623 2629
9. K. West CP-690550 a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders Curr Opin Investig Drugs 10 2009 491 504
10. M.G. Boy, C. Wang, B.E. Wilkinson, V.F. Chow, A.T. Clucas, and J.G. Krueger Double-blind, placebo controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis J Invest Dermatol 129 2009 2299 3029
11. Tasocitinib. Drugs R D. 2010;10:271-84.
12. M. Maiga, S. Lun, H. Guo, K. Winglee, N.C. Ammerman, and W.R. Bishai Risk of tuberculosis reactivation with tofacitinib (CP-690550) J Infec Dis 205 2012 1705 1708
13. M. Pesu, A. Laurence, N. Kishore, S.H. Zwillich, G. Chan, and J.J. O'Shea Therapeutic targeting of Janus kinases Immunol Rev 223 2008 132 142
14. W. Vainchenker, A. Dusa, and S.N. Constantinescu JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies Semin Cell Dev Biol 19 2008 385 393
15. N. Punwani, P. Scherle, R. Flores, J. Shi, J. Liang, and S. Yeleswaram Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis J Am Acad Dermatol 67 2012 658 664
16. B.Y. Chang, F. Zhao, X. He, H. Ren, S. Braselmann, and V. Taylor JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice J Immunol 183 2009 2183 2192
17. S. Braselmann, V. Taylor, H. Zhao, S. Wang, C. Sylvain, and M. Baluom R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation J Pharmacol Exp Ther 319 2006 998 1008
18. M.E. Weinblatt, A. Kavanaugh, M.C. Genovese, T.K. Musser, E.B. Grossbard, and D.B. Magilavy An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis N Engl J Med 363 2010 1303 1312
19. M.C. Genovese, A. Kavanaugh, M.E. Weinblatt, C. Peterfy, J. Dicarlo, and M.L. White An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents Arthritis Rheum 63 2011 337 345
20. E. Wierzbicka, J.M. Tourani, and G. Guillet Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma: a role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 155 2006 213 214
21. E. Giroux Leprieur, S. Friard, and L.J. Couderc Improvement of psoriasis in a lung cancer patient treated with erlotinib Eur J Dermatol 20 2010 243 244
22. N. Oyama, F. Kaneko, A. Togashi, and T. Yamamoto A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma J Am Acad Dermatol 66 2012 e251 e253
23. M. Matz, M. Naik, M.F. Mashreghi, P. Glander, H.H. Neumayer, and K. Budde Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation Expert Opin Drug Metab Toxicol 7 2011 103 113
24. A. Golant, and E. Guttman-Yassky Psoriasis treatments: A review of the current research pipeline Psoriasis Forum 17 2011 11 23
25. H. Skevara The PKC inhibitor AEB071 may be a therapeutic option for psoriasis J Clin Invest 118 2008 3151 3159
26. A. Abbas, and A. Lichtman Inmunidad frente a los microbios. Inmunología celular y molecular 2004 Elsevier Madrid p. 354
27. D. Hammaker, and G.S. Firestein Go upstream, young man: lessons learned from the p38 saga Ann Rheum Dis 69 Suppl 1 2010 i77 i82